Health TrialsbyHealthPanel

Delineation of Target Volume of Stereotactic Radiotherapy for Spinal Tumors

ConditionSpinal Tumor
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-90
SponsorPeking University Third Hospital

About this trial

The purpose of this study was to compare efficacy and side effects of two target delineation methods for stereotactic radiotherapy of metastatic spinal tumors.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients with spinal metastases or primary tumors receiving stereotactic radiotherapy;

Patients with sufficent pre-treatment imaging data

Patients who can cooperate with imaging review and follow-up after radiotherapy.

Disqualifiers

Patients with an expected survival of less than 3 months;

Patients with second-course radiotherapy;

Patients with physical conditions that cannot tolerate stereotactic radiotherapy;

Patients with extensive spinal metastasis and no local therapeutic value

Trial population

Patients with malignant tumor spinal metastasis who received or will receive stereotactic radiotherapy, without preoperation.

Trial design

Design model

Cohort

Time perspective

Other

Treatments tested in this trial

  • Target volume delineation

    Radiation

    Group 1(small target delineation)：The target bolume only includes local tumor. Group 2(small target delineation)：The target bolume includes local tumor and adjacent vertebral area.

Treatment groups

500 Participants
are divided into 2 treatment groups
Group A: group 11 intervention
Group B: group 21 intervention

Trial outcomes

Primary outcomes

1

Disease Control Rate（DCR）

Disease Control Rate（DCR），including complete response（CR），partial response(PR) and stable disease(SD ).

Time frame
2 years
2

Pain relief rate

VAS Score(Visual Analog Scale Score) decreased after treatment

Time frame
3 months

Secondary outcomes

1

Incidence of side effects

radiation myelitis,radiation esophagitis, etc.

Time frame
2 years

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Peking University Third Hospital

Lead sponsor

Source ClinicalTrials.gov
Apply now